Business
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced...
Hi, what are you looking for?
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced...
Teva says it will seek ‘further appellate review’
Teva is now close to the 4.6% stake in Mylan that will give it standing in the Netherlands courts.
Mylan has confirmed it will dual list on the TASE and Nasdaq if it acquires Perrigo
Abbott Laboratories (NYSE: ABT), said it would back the generic pharmaceutical company Mylan’s (MYL) $34 billion bid acquisition of Perrigo Co Plc (PRGO.N). Abbott...
A Credit Suisse study finds that most hostile bids fail, especially if antitrust concerns are involved.
Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, are pushing Mylan to take Teva’s $40 billion take-over bid offer seriously.
In the 7th Jun 2015 edition of Israel’s good news, the highlights include: A new Israeli device uses light to identify bacterial infections in...
Bolt-on acqusition strengthens position in Europe amid three-way takeover battle with Mylan and Teva
Three Way Takeover Battle: believes their offer will win approval from Perrigo stockholders.